Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- Acronyms BEAT-ROP
Most Recent Events
- 21 Feb 2016 Planned End Date changed from 1 Oct 2017 to 1 Aug 2020 as per ClinicalTrials.gov record.
- 18 Sep 2015 New trial record